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bjectives This study assessed the effect of pharmacogenetics on the antiplatelet effect of
lopidogrel.
ackground Variability in clopidogrel response might be inﬂuenced by polymorphisms in genes
oding for drug metabolism enzymes (cytochrome P450 [CYP] family), transport proteins (P-
lycoprotein) and/or target proteins for the drug (adenosine diphosphate–receptor P2Y12).
ethods Sixty patients undergoing elective percutaneous coronary intervention in the randomized
RINC (Plavix Response in Coronary Intervention) trial had platelet function measured using the Veri-
yNow P2Y12 analyzer after a 600-mg or split 1,200-mg loading dose and after a 75- or 150-mg daily
aintenance dosage. Polymerase chain reaction–based genotyping evaluated polymorphisms in the
YP2C19, CYP2C9, CYP3A4, CYP3A5, ABCB1, P2Y12, and CES genes.
esults CYP2C19*1*1 carriers had greater platelet inhibition 2 h after a 600-mg dose (median: 23%,
ange: 0% to 66%), compared with platelet inhibition in CYP2C19*2 or *4 carriers (10%, 0% to 56%,
 0.029) and CYP2C19*17 carriers (9%, 0% to 98%, p  0.026). CYP2C19*2 or *4 carriers had
reater platelet inhibition with the higher loading dose than with the lower dose at 4 h (37%, 8% to
7% vs. 14%, 0% to 22%, p  0.002) and responded better with the higher maintenance dose regi-
en (51%, 15% to 86% vs. 14%, 0% to 67%, p  0.042).
onclusions Carriers of the CYP2C19*2 and *4 alleles showed reduced platelet inhibition after a clo-
idogrel 600-mg loading dose but responded to higher loading and maintenance dose regimens.
enotyping for the relevant gene polymorphisms may help to individualize and optimize clopi-
ogrel treatment. (Australia New Zealand Clinical Trials Registry; ACTRN12606000129583) (J Am
oll Cardiol Intv 2008;1:620–7) © 2008 by the American College of Cardiology Foundation
rom *Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; and †Department of Medical
ciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden. Funded in part by the Green Lane Research and
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621lopidogrel, an adenosine diphosphate receptor (P2Y12)
locker, is clinically used to prevent thrombotic events (1).
he response to clopidogrel shows a wide interindividual
ariation (2), with 5% to 30% of patients not responding to
nitial clopidogrel therapy (3,4). Clopidogrel is a prodrug
hat requires conversion to its active thiol derivative cata-
yzed predominantly by cytochrome P450 (CYP) 3A4 and
A5, with contributions from 2C19, 2C9, and 1A2 en-
ymes (5–7). Several studies (6,8–10) have evaluated the
mpact of polymorphisms in genes encoding enzymes in-
olved in clopidogrel metabolism (CYP2C19, CYP2C9,
YP3A4, and CYP1A2), as well as polymorphisms of
-glycoprotein transporter protein coding gene (ABCB1),
n clopidogrel response.
See page 628
The activity of CYP3A4, measured by radiolabeled eryth-
omycin breath testing, correlates with the response to
lopidogrel (11). CYP3A4 expression may be variable due in
art to polymorphisms in the gene coding this enzyme,
ncluding CYP3A4*1B, CYP3A4*3, and CYP3A4*4 (12–14).
hese variants are uncommon in Caucasians (15,16), with
nly 1 CYP3A4 polymorphism (IVS1012GA) reported
o date to be associated with a reduced response to clopi-
ogrel (10,17). Expression of the CYP3A5 enzyme occurs
nly in subjects carrying at least 1 CYP3A5*1 allele, which is
resent in up to 15% of Caucasians (18). Subjects carrying
he CYP3A5*1 allele appear to have greater platelet inhibi-
ion and fewer atherothrombotic events after percutaneous
oronary intervention (PCI) than those who do not have
his allele (7).
A number of well-described polymorphisms exist within
he CYP2C19 and CYP2C9 genes. The CYP2C19*2, *3, and
4 alleles display a loss of function of this enzyme, and
YP2C19*17 is associated with ultrarapid enzyme activity
19). CYP2C19*2 carriers have a reduced antiplatelet re-
ponse to a 300-mg loading dose (6) and to a 75-mg daily
aintenance dosage of clopidogrel (9,10). Similarly,
YP2C9*2 and CYP2C9*3 code for enzymes with decreased
ctivity compared with CYP2C9*1 allele, and the CYP2C9*2
llele has been associated with a reduced response to a
lopidogrel 300-mg loading dose (20).
The ISAR-CHOICE (Intracoronary Stenting and An-
ithrombotic Regimen: Choose Between 3 High Oral Doses
or Immediate Clopidogrel Effect) study (21) supports the
dea that the apparent ceiling antiplatelet effect with clopi-
ogrel 600 mg is due to saturable intestinal absorption of
he drug, mediated by the P-glycoprotein efflux pump. A
olymorphism of the ABCB1 gene (C3435T) influences
lasma levels of clopidogrel and its active metabolite;
atients with the 3435T/T genotype have lower maximum
oncentration and area-under-the-curve values for both Alopidogrel and its active metabolite compared with these
alues in 3435C/T and 3435C/C carriers, after 300- or
00-mg single loading doses (22). However, the polymor-
hism has not been related to the antiplatelet activity of
lopidogrel.
A haplotype of the P2Y12 gene, denoted H2, consists of
single nucleotide polymorphisms (SNPs) (intronic
i]-C139T, i-T744C, i-ins801A, C34T, and G52T) (23).
s the SNPs occur in complete linkage disequilibrium, they
an be tagged by the intronic SNP (i-T744C) (24). Hap-
otype H2 is associated with increased platelet responsive-
ess to adenosine diphosphate but does not appear to
nfluence the response to clopidogrel (23,25). Plasma car-
oxylesterases break down the active metabolite of clopi-
ogrel (26). Although the carboxylesterase gene (CES) is
ell conserved, a polymorphism has been described that
ecreases messenger ribonucleic acid transcription (27).
We evaluated the impact of polymorphisms in a number
f genes to determine whether they influence response to
lopidogrel therapy as part of a randomized, placebo-
ontrolled trial comparing the antiplatelet effect of a split
ose 1,200-mg clopidogrel loading dose with a standard
00-mg loading dose and com-
aring a 150-mg daily dose with
75-mg daily maintenance dos-
ge in patients undergoing PCI.
ethods
he study protocol (Fig. 1),
aseline patient characteristics,
nd additional pharmacothera-
ies are described in the accompanying report (28) in this
ssue of JACC: Cardiovascular Interventions.
enotyping. Deoxyribonucleic acid was extracted from
hole blood using the QIAamp DNA Blood Mini Kit
QIAGEN N.V., Venlo, the Netherlands) and stored at
20°C. Genes of interest were identified using a candidate
ene approach (Table 1). The CYP3A4*1B (16), CYP3A4*3
15), CYP3A4*4 (12), and CYP2C19*17 (19) polymorphisms
ere identified by polymerase chain reaction–restriction
ragment length polymorphism methods previously de-
cribed and the CYP3A5*3, CYP3A5*2, CYP3A5*6,
YP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C9*2,
YP2C9*3, and ABCB1 1236CT, 3435CT,
677GA/T polymorphisms were investigated by real-time
olymerase chain reaction using TaqMan kits (Applied
iosystems, Foster City, California) and ABI PRISM 7000
equence Detection System (Applied Biosystems) at the
epartment of Medical Science, Clinical Pharmacology,
ppsala University, Uppsala, Sweden. Genotyping for the
2Y12 H2 haplotype and carboxylesterase intronic SNP
IVS10-88) was performed using iPlex assays on the
Abbreviations
and Acronyms
CYP  cytochrome P450
i  intronic
PCI  percutaneous
coronary intervention
SNP  single nucleotide
polymorphismutoflex mass spectrometer (Sequenom, San Diego, Cali-
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622ornia). Genotyping using the Sequenom mass spectrometer
as performed at the Australian Genome Research Facility
University of Queensland, St. Lucia, Australia).
tatistical analysis. The sample size was determined by the
umber needed to detect differences between the treatment
Figure 1. Timetable of the Study Protocol
A double-blind, randomized, placebo-controlled trial with 2  2 factorial desig
intervention.
Table 1. Candidate SNPs Associated With Clopidogrel Response in the Lite
Allele SNP
dbSNP Reference
Sequence No.
ABCB1*2 1236CT rs1128503 Incre
3435CT rs1045642
2677GT/A rs2032582
CYP3A4*1B 392AG rs2740574 Redu
CYP3A4*3 23171TC rs4986910 Redu
CYP3A4*4 13871AG — Redu
CYP3A5*1 6986GA 31611TC rs776746 Norm
CYP3A5*3 6986AG Nonf
CYP2C19*1 — — Norm
CYP2C19*2 19154GA rs4244285 Lack
CYP2C19*4 1AG rs28399504 Lack
CYP2C19*17 806CT rs12248560 Incre
CYP2C9*1 — — Norm
CYP2C9*2 3608CT rs1799853 Redu
CYP2C9*3 42614AC rs1057910 Redu
P2Y12 H2 haplotype i-T744C rs2046934 Incre
CES2 g.275AG rs1464602 Redu
Intronic SNP (IVS10-88) rs3893757 Redu
— information not available. *1 normal variants are denoted by the absence of variant SNPs.
ABCB1  P-glycoprotein gene; ADP  adenosine diphosphate; CES  carboxylesterase; CYPpolymorphism.egimens evaluated in the PRINC (Plavix Response in
oronary Intervention) study. Genotyping was undertaken
s a secondary analysis. Results are reported as median and
ange, unless otherwise specified. A receiver operator char-
cteristic was used to assess the predictive value of percent-
undertaken in 60 patients undergoing elective percutaneous coronary
e
nctional Effect
Effect on
Clopidogrel Response Reference #
testinal efﬂux of drugs — —
Negative Taubert et al. (22)
— —
zyme function None Angiolillo et al.(17)
zyme function None Angiolillo et al. (17)
zyme function — —
yme function Positive Suh et al. (7)
nal enzyme Negative Suh et al. (7)
yme function Normal Romkes et al. (36)
Fontana et al. (10)
Hulot et al. (9)
Brandt et al. (6)
yme activity Negative Fontana et al. (10)
Hulot et al. (9)
Brandt et al. (6)
yme activity — —
nzyme function — —
yme function Normal Brandt et al. (6)
zyme function Negative Brandt et al. (6)
zyme function Negative Brandt et al. (6)
latelet response to ADP None Von Beckerath et al. (21)
idazolam clearance — —
RNA gene expression — —
chrome P450; db  database; mRNA  messenger ribonucleic acid; SNP  single nucleotiden wasratur
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623ge platelet inhibition at 2 h, compared with the percentage
t 7 h. The Kruskal-Wallis test was used to compare 3 or
ore genotype groups and the Mann-Whitney U test was
sed to compare 2 genotype groups for platelet inhibition as
percentage of the baseline platelet activity using GraphPad
rism 4 (GraphPad Software, San Diego, California).
Figure 2. Prediction of Late Platelet Inhibition Based on Platelet Inhibi-
tion at Earlier Time Intervals After Clopidogrel Dosing
Pearson correlation matrix showing the relationship between platelet func-
tion response at different time intervals. Platelet inhibition of 2% at 2 h
predicted nonresponse at 7 h (inhibition 10%), with a sensitivity of 100%
and a speciﬁcity of 88%.
Table 2. Frequency of Detectable Variant Alleles in Our Study Population a
Allele SNP
dbSNP Reference
Sequence No.
ABCB1*2 1236CT rs1128503
3435CT rs1045642
2677GT/A rs2032582
CYP3A5*3 6986AG —
CYP2C19*2 19154GA rs4244285
CYP2C19*4 1AG rs28399504
CYP2C19*17 –806CT rs12248560
CYP2C9*2 3608CT rs1799853
CYP2C9*3 42614AC rs1057910
P2Y12 H2 haplotype i-T744C rs2046934
Dash denotes information not available.CEU Caucasian; other abbreviations as in Table 1.nalysis of covariance was used to assess the influence of
enotyping for CYP2C19 and CYP2C9 polymorphisms and
lopidogrel dose on the variance in maximal platelet inhi-
ition using SAS (version 9.1) and R (version 2.1.1)
oftware (SAS Institute, Cary, North Carolina). Statistical
djustment for multiple hypothesis testing was not used.
esults
he effect of different clopidogrel loading and maintenance
ose regimens on platelet inhibition is reported in the
ccompanying report (28).
rediction of response with phenotyping. A receiver-
perator characteristic analysis found that lack of platelet
nhibition at 2 h predicted clopidogrel resistance at 7 h (p
.02) (Fig. 2). There were fewer nonresponders in the
,200-mg group than in the 600-mg group; 2 of 37 in the
igh-dose group (5%) compared with 6 of 26 in the
ow-dose group (26%) had 7-h platelet inhibition 10%.
he area under the curve for these receiver-operator char-
cteristic curves was 0.90. Platelet inhibition of less than 2%
t 2 h was the best predictor of nonresponse (inhibition
10%) in all patients, regardless of dose, at 7 h (sensitivity
00% and specificity 88%).
rediction of response with genotyping. The frequency of
he genotypes tested in our study population and previously
eported frequencies in Caucasians are outlined in Table 2.
YP3A4/5 POLYMORPHISMS. None of the patients carried the
YP3A4*1B, *3, *4, or CYP3A5*2 and *6 variant alleles, but
patients had the CYP3A5*1*1 genotype, and 3 patients had
he CYP3A5*1*3 genotype. However, no significant differ-
nce was observed in platelet inhibition in those with the
YP3A5 genotype (data not shown).
ose Reported in Hapmap Database
SNP Frequency Cohort Versus Hapmap (CEU)
Homozygotes Heterozygotes
Cohort Hapmap Cohort Hapmap
0.13 0.13 0.62 0.52
0.22 0.24 0.63 0.60
0.12 0.11 0.6 0.56
0.92 0.88 0.05 0.12
0 0.05 0.27 0.21
0 — 0.05 —
0.07 0.02 0.27 0.40
0.02 0 0.25 0.21
0 0 0.05 0.12
0.03 0.03 0.25 0.38nd Th
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624YP2C19 AND CYP2C9 POLYMORPHISMS. None of the patients
arried the CYP2C19*3 allele. The frequency of the
YP2C19*17 allele was 20% in our study population, which
s similar to that reported in Swedish and Ethiopian subjects
18%) and higher than in a Chinese population (4%) (19).
latelet inhibition 2 h after a 600-mg dose was greater in
YP2C19*1*1 carriers (median: 23%, range: 0% to 66%)
han in CYP2C19*2 or *4 carriers (10%, 0% to 56%, p 
.029) and CYP2C19*17 carriers (9%, 0% to 98%, p 
.026) (Fig. 3). The platelet inhibition did not differ
ignificantly in CYP2C19*1*1 carriers after a 1,200- and
00-mg loading dose at 4 h (43%, 13% to 97% and 35%, 0%
o 65%, respectively, p 0.3) (Fig. 4) and 7 h (63%, 15% to
8% and 29%, 0% to 75%, respectively, p  0.05) and after
150- and 75-mg daily maintenance dosage (46%, 18% to
7% and 32%, 24% to 64%, respectively, p  0.2) (Fig. 4).
n contrast, CYP2C19*2 or *4 carriers had greater platelet
nhibition with the higher 1,200-mg loading dose than with
00 mg at 4 h (37%, 8% to 87% and 14%, 0% to 22%,
espectively, p  0.002) (Fig. 5) and tended to show a
imilar trend at 7 h (42%, 7% to 94% and 22%, 0% to 51%,
espectively, p  0.09). Similarly, platelet inhibition was
ignificantly greater with the 150-mg dose than the 75-mg
aily maintenance dosage regimen (51%, 15% to 86% and
4%, 0% to 67%, respectively, p  0.042) (Fig. 5).
The CYP2C9 genotype did not significantly influence the
latelet response, except that CYP2C9*1*3 carriers had
educed platelet inhibition compared with platelet inhibi-
ion in CYP2C9*1*1 carriers at 7 h with the 600-mg
lopidogrel dose (9%, 8% to 11% and 31%, 0% to 96%,
espectively, p  0.045).
Individuals were aggregated based upon their CYP2C19
Figure 3. Platelet Inhibition (% of Baseline) at 2 h After a 600-mg Clopi-
dogrel Loading Dose in CYP2C19 Genotype Groups
CYP2C19*1*1 carriers have greater platelet inhibition 2 h after a 600-mg
dose compared with platelet inhibition in CYP2C19*2 or *4 carriers and
CYP2C19*17 carriers.nd CYP2C9 genotype status as either predictive of response dCYP2C19*1*1 or CYP2C9*1*1 or *2 carriers) or predictive of
oor response (CYP2C19*2 or *4 or *17 or CYP2C9*3), as
as been described previously (6). Despite the different
Figure 4. Platelet Inhibition (% of Baseline) at 4 h, 7 h, and 7 Days After
Clopidogrel Loading in CYP2C19*1*1 Carriers
CYP2C19*1*1 carriers had similar platelet inhibition after a 1,200- and
600-mg loading dose at 4 h (A), 7 h (B), and after a 150 and 75 mg daily
maintenance dosage (C).osing regimens of clopidogrel, platelet inhibition at 7 h was
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625ignificantly influenced by having a poor-response genotype
p  0.04, Mann-Whitney U test). Two individuals who
Figure 5. Platelet Inhibition (% of Baseline) at 4 h, 7 h, and 7 Days After
Clopidogrel Loading in CYP2C19*2 or *4 Carriers
CYP2C19*2 or *4 carriers had greater platelet inhibition, with the higher
loading dose than with the lower dose at 4 h (A) and responded better
with the higher maintenance dosage regimen (B) 7 h; (C) after 150 and 75
mg daily maintenance dose.ere compound heterozygotes for both CYP2C19 *2 and pYP2C9 *3 genotypes had platelet inhibition of 8% and 11%
t 7 h, respectively.
Analysis of covariance was used to compare the influence
f genetics, which expressed as number of variants, with that
f clopidogrel dose on platelet inhibition at 7 h. The F
alues of 8.3 for clopidogrel dose (p  0.006) and 5.9 for
enetics (p  0.02) indicate that both the clopidogrel dose
nd genotype influence the variance in maximal platelet
nhibition.
BCB1 POLYMORPHISMS. No significant influence of ABCB1
olymorphisms on platelet response was observed at any time
nterval.
2Y12 H2 HAPLOTYPE. Patients homozygous for the P2Y12
2 haplotype denoted by the insertion variation i-T744C
ere uncommon; only 2 subjects were CC homozygotes.
lthough neither had a high baseline peripheral resistance
nit value, platelet inhibition 2 h after 600-mg clopidogrel
as 2% in both individuals.
ES POLYMORPHISMS. The carboxylesterase intronic SNP
IVS10-88) was not present in this cohort.
iscussion
atients carrying the CYP2C19*2, CYP2C19*4, and
YP2C19*17 alleles have a decreased antiplatelet response
o clopidogrel compared with the response of CYP2C19*1*1
arriers. Patients carrying any of these alleles displayed both
reduced early response to clopidogrel loading and a
educed sustained response after 1 week of maintenance
herapy. CYP2C19 appears to be important in the first step
n biotransformation of the parent drug into the active
etabolite, and a loss of function in this enzyme system
eads to a reduction in the plasma levels of the active
etabolite (6).
The CYP3A4 variant alleles are uncommon in a predom-
nantly Caucasian population. As few patients carried the
ariants, the potential influence of CYP3A4 polymorphisms
n clopidogrel response could not be assessed. Moreover, in
he 6 patients who carried the CYP3A5*1 allele, no signifi-
ant impact of CYP3A5 expression was observed on clopi-
ogrel response.
The finding of reduced platelet inhibition in patients with
he CYP2C19*17 allele is unexpected given that *17 codes
or an enzyme with higher activity than *1 does (19). To our
nowledge, this is the first study to evaluate the impact of
YP2C19*4 and *17 on clopidogrel response.
Several previous studies (6,9,10) have shown that the
YP2C19*2 allele is associated with a reduced antiplatelet
esponse to clopidogrel therapy. Hulot et al. (9) found that
eterozygote CYP2C19*2 subjects had no significant change
n platelet function after 7 days of clopidogrel 75 mg daily,
s assessed by both 10-mol/l adenosine diphosphate light
ransmittance aggregometry and vasodilator-stimulated
hosphorylation. In another normal subject cohort, plate-
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626et inhibition after clopidogrel 75 mg daily for 1 week,
easured by 20 mol/l adenosine diphosphate aggre-
ometry, was significantly reduced in subjects carrying
he CYP2C19*2 allele (10). Brandt et al. (20) found that
he CYP2C9*2 and *3 alleles, in addition to the
YP2C19*2 allele, influence the plasma levels of clopi-
ogrel active metabolite as well as the response to
lopidogrel. These variants are not in linkage disequilib-
ium and, when considered together, reportedly ac-
ounted for two-thirds of poor responders. The third-
eneration thienopyridine, prasugrel, is not as dependent
n either the CYP2C19 or CYP2C9 enzymes for meta-
olic activation (6).
Patients given a split 1,200-mg clopidogrel loading dose
nd a 150-mg daily maintenance dosage had greater platelet
nhibition than 600 mg and 75 mg, respectively. Inter-
stingly, the higher clopidogrel loading and maintenance
ose regimens achieved greater platelet inhibition in
YP2C19*2 or *4 carriers compared with inhibition in lower
ose regimens, whereas a dose-dependent response was not
bserved in CYP2C19*1*1 carriers. In other words, those
ith the poor-response genotype may specifically benefit
rom a higher dose of clopidogrel. However, the numbers in
his study are small and this finding requires confirmation in
dose escalation study with larger patient numbers.
The CYP2C19*2 allele is present in 13% of Caucasians,
8% of African Americans, and 29% of East Asians (29).
he higher frequency of the CYP2C19*2 allele in Chinese
uggests that there may be ethnic differences in clopidogrel
esponse. Although an ethnicity-based treatment approach,
uch as targeting the antihypertensive drug BiDil to African
mericans, has yet to be widely accepted (30), potential
ifferences among ethnic groups in drug response should be
onsidered when evaluating trial data.
Drugs that are competitively metabolized or inhibit the
ctivity of CYP2C19 also have the potential to reduce the
ctivity of clopidogrel. This drug interaction has recently
een shown with omeprazole (10,31,32) and may theoreti-
ally also occur with phenytoin and fluoxetine. The clinical
ignificance of this interaction remains uncertain.
tudy limitations. The major limitation of this study is the
opulation size, which particularly affects assessment of the
nfluence of the less common genotypes. As there were only
subjects with compound heterozygosity for CYP2C19 and
YP2C9 with a poor response to clopidogrel, the suggestion
hat a combination of genotypes may be more predictive of
lopidogrel response than 1 genotype remains a hypothesis
ith initial supportive data. A recent study has suggested a
ene-gene interaction between the P2Y12 haplotype and the
YP2C19*2 variant (33). Although a poor response to
lopidogrel has been associated with an increase in peripro-
edural myonecrosis during PCI (34), it remains to be
hown whether these genotypes will predict those at in-
reased risk for vascular atherothrombotic complicationshile on clopidogrel and whether some of those complica-
ions will be prevented by an individualized, higher dose
reatment regimen targeting carriers of CYP2C19*2 and *4
enotypes. A recent study of 797 patients undergoing PCI
ailed to show a relationship between the CYP2C19*2
enotype and cardiovascular events (35). Larger clinical
rials are also needed to confirm the merits of a genotype-
ocused dosing approach over individualized treatment
ased on either laboratory or point-of-care platelet function
nalysis.
onclusions
his study provides evidence for the impact of CYP2C19
enotype on the platelet response to clopidogrel and shows
hat higher-dose clopidogrel regimens can increase the
egree of platelet inhibition in patients with genotypes
redictive of poor response. Personalized therapy targeting
atients who carry the CYP2C19 variants predictive of poor
esponse may help to improve clinical outcomes and the
ost–benefit of treatment.
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